Vepafestinib

  Cat. No.:  DC47018  
Chemical Structure
2129515-96-2
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Vepafestinib (compound 6) is a RET inhibitor (extracted from patent WO2019039439).
Cas No.: 2129515-96-2
Chemical Name: Vepafestinib
Formula: C26H30N6O3
M.Wt: 474.55
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC47314 TPX-0046 TPX-0046 is a novel RET/SRC inhibitor with a mean IC50 of 17 nM for RETG810R in Ba/F3 cell proliferation assay.,RET [1]() SRC [1]()
DC47129 Zeteletinib Zeteletinib (BOS-172738) shows selective inhibitory activity against RET, PDGFR, KIT, NTRK and FLT3 kinases. Zeteletinib has antitumor activity.
DC47018 Vepafestinib Vepafestinib (compound 6) is a RET inhibitor (extracted from patent WO2019039439).
DC40626 RET-IN-3 RET-IN-3 (compound 34) is a selective RETV804M kinase inhibitor, with an IC50 of 19 nM.
DC40625 WF-47-JS03 WF-47-JS03 is a potent and selective RET kinase inhibitor with IC50s of 1.7 nM and 5.3 nM for KIF5B-RET transfected Ba/F3 cells and CCDC6-RET transfected LC-2/ad lung cancer cells, respectively. WF-47-JS03 demonstrates >500-fold selectivity against kinase insert domain receptor (KDR). Effective brain penetration.
DC10058 BBT594 BBT594 (NVP-BBT594), is potent and selective inhibitor of RET and JAK2.
X